Tafamidis (Vyndamax or Vyndaqel) is one of the most well-studied treatments for ATTR amyloidosis, and the survival data is genuinely encouraging. It works by acting like a kind of "molecular glue," keeping the TTR protein in its correct shape so it doesn't break apart and form amyloid deposits.
Here's what the research Show Full Answer
Tafamidis (Vyndamax or Vyndaqel) is one of the most well-studied treatments for ATTR amyloidosis, and the survival data is genuinely encouraging. It works by acting like a kind of "molecular glue," keeping the TTR protein in its correct shape so it doesn't break apart and form amyloid deposits.
Here's what the research shows about survival outcomes:
- In a large study of over 3,000 people with hATTR polyneuropathy, 93% of people treated with tafamidis were still alive at 10 years
- For those diagnosed before age 50, tafamidis reduced the risk of death by 91% compared to no treatment
- For those diagnosed at age 50 or older, the risk of death was 82% lower with tafamidis than without it
- Long-term studies also show tafamidis can improve heart function and help people manage daily tasks like walking and exercise Starting treatment early appears to make a significant difference in outcomes. The sooner tafamidis is begun, the better the results tend to be.
It's also approved for both hereditary and wild-type ATTR cardiomyopathy, making it relevant across different forms of the condition. Talking with a specialist about when and how to start tafamidis is an important step in building a personalized treatment plan.
September 10
Join
Your Privacy Choices
